Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Erythematotelangiectatic Rosacea: later-stage trial registry
A small indexed set (3 trials) with no open enrollment listed right now.
Corpus placement: #5,209 of 28,707 conditions by registered trial count.
3 US clinical trials · none currently recruiting · #5,209 of 28,707 conditions by registered trial count
Erythematotelangiectatic Rosacea: 3 US clinical trials tracked, none currently recruiting.
Erythematotelangiectatic Rosacea is the subject of 3 registered US clinical trials on ClinicalTrials.gov, none currently recruiting. 2 are in Phase 3-4 (later-stage) and 0 in Phase 1-2 (earlier-stage). The most active sponsor is bioRASI, running 1 of these trials.
Enrollment posture brief
Registry condition erythematotelangiectatic-rosacea
OPEN 0 | RECR 0% | LATE 2 | EARLY 0 | RANK #5209 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Accelerated Phase Chronic Myelogenous Leukemia (0% recruiting · 12 trials)
Erythematotelangiectatic Rosacea has no open enrollment in this registry pull (3 archived studies). Peers show how other volume-matched labels compare on open share. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Erythematotelangiectatic Rosacea on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Erythematotelangiectatic Rosacea is recruiting below its size-band peers.
0 of 3 indexed trials (0%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Indexed trials (enrollment closed)
3 total, page 1 of 1
A Therapeutic Equivalence Study of Two Metronidazole Gel 1% Topical Treatments of Rosacea
bioRASI
NCT02393937
Pulsed Dye Laser Treatment and Oxymetazoline Hydrochloride (HCL) 1% Cream for Erythematotelangiectatic Rosacea
Candela Corporation
NCT04153188
Excel V 532 nm KTP Laser for Treatment of Erythematotelangiectatic Rosacea & Papulopustular Rosacea
Cutera
NCT02268474
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 3 | 1 |
| Phase 4 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Erythematotelangiectatic Rosacea records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Erythematotelangiectatic Rosacea trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Erythematotelangiectatic Rosacea page
3 registered trials, 0 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- No Erythematotelangiectatic Rosacea trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- bioRASI sponsors the most Erythematotelangiectatic Rosacea trials on record, review their full trial history before evaluating a specific study. See bioRASI's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Erythematotelangiectatic Rosacea condition card totals 3 registered trials; most-linked intervention Oxymetazoline HCL 1% Cream; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.